Compare LOCL & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCL | TVRD |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | 333 | 12 |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6M | 29.1M |
| IPO Year | N/A | N/A |
| Metric | LOCL | TVRD |
|---|---|---|
| Price | $2.57 | $3.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | ★ 2.1M | 48.4K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $97.19 | N/A |
| Revenue Next Year | $33.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.98 | $2.75 |
| 52 Week High | $4.00 | $43.65 |
| Indicator | LOCL | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 68.52 | 48.65 |
| Support Level | $2.20 | $2.75 |
| Resistance Level | $2.75 | $3.50 |
| Average True Range (ATR) | 0.26 | 0.23 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 68.85 | 55.22 |
Local Bounti Corp is a controlled environment agriculture company. Its business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides, it delivers products that have a longer shelf life, and are good in taste.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.